2012 Nationally Notifiable Diseases and Conditions and Current Case Definitions

Prepared by: The Division of Notifiable Diseases and Healthcare Information (proposed) Public Health Surveillance and Informatics Program Office (proposed) Office of Surveillance Epidemiology and Laboratory Services Centers for Disease Control and Prevention

Case Definitions based upon CSTE Position Statements available at www.CSTE.org

Suggested Citation 2012 Case Definitions: Nationally Notifiable Conditions Infectious and Non-Infectious Case. (2012). Atlanta, GA: Centers for Disease Control and Prevention

2

Index Nationally Notifiable Infectious and Non-Infectious Conditions

Infectious Conditions Anthrax Arboviral neuroinvasive and non-neuroinvasive diseases • California serogroup virus disease • Eastern equine encephalitis virus disease • Powassan virus disease • St. Louis encephalitis virus disease • West Nile virus disease • Western equine encephalitis virus disease Babesiosis Botulism • Botulism, foodborne • Botulism, infant • Botulism, other (wound & unspecified) Chlamydia trachomatis infection Coccidioidomycosis Cryptosporidiosis Cyclosporiasis Dengue • Dengue Fever • Dengue Hemorrhagic Fever • Dengue Shock Syndrome Diphtheria / • • • Anaplasma phagocytophilum • Undetermined Free-living Amebae, Infections caused by Giardiasis influenzae, invasive disease Hansen disease () Hantavirus pulmonary syndrome Hemolytic uremic syndrome, post-diarrheal

3

Hepatitis • Hepatitis A, acute • Hepatitis B, acute • Hepatitis B, chronic • Hepatitis B virus, perinatal infection • Hepatitis C, acute • Hepatitis C, past or present HIV infection (AIDS has been reclassified as HIV stage III) • HIV infection, adult/ adolescent (age > = 13 years) • HIV infection, child (age >= 18 months and < 13 years) • HIV infection, pediatric (age < 18 months) Influenza-associated hospitalizations Influenza-associated pediatric mortality Legionellosis Listeriosis Lyme disease Malaria Measles Mumps Novel influenza A virus infections Pertussis Poliomyelitis, paralytic Poliovirus infection, nonparalytic Psittacosis • Acute • Chronic Rabies • Rabies, animal • Rabies, human Rubella (German Measles) Rubella, congenital syndrome Severe Acute Respiratory Syndrome-associated Coronavirus (SARS-CoV) disease Shiga toxin-producing (STEC) Smallpox Spotted Fever Streptococcal toxic-shock syndrome Streptococcus pneumoniae, invasive disease

4

Syphilis • Primary • Secondary • Latent • Early latent • Late latent • Latent, unknown duration • Neurosyphilis • Late, non-neurological • Stillbirth • Congenital Tetanus Toxic-shock syndrome (other than Streptococcal) Trichinellosis (Trichinosis) Vancomycin - intermediate Staphylococcus aureus (VISA) Vancomycin - resistant Staphylococcus aureus (VRSA) Varicella (morbidity) Varicella (deaths only) Vibriosis Viral Hemorrhagic Fevers, due to: • Ebola virus • Marburg virus • Crimean-Congo Hemorrhagic Fever virus • Lassa virus • Lujo virus • New world arenaviruses (Gunarito, Machupo, Junin, and Sabia viruses) Yellow fever

Nationally Notifiable Non-Infectious Conditions Cancer Elevated blood lead levels • Child (<16 years) • Adult (≥16 Years) Foodborne disease outbreak Pesticide-related illness, acute Silicosis Waterborne disease outbreak

5

Anthrax (Bacillus anthracis) 2010 Case Definition CSTE Position Statement Number: 09-ID-10

Clinical description Cutaneous Anthrax: An acute illness, or post-mortem examination revealing a painless skin lesion developing over 2 to 6 days from a papular through a vesicular stage into a depressed black eschar with surrounding edema. Fever, malaise and lymphadenopathy may accompany the lesion.

Inhalation Anthrax: An acute illness, or post-mortem examination revealing a prodrome resembling a viral respiratory illness, followed by hypoxia, dyspnea or acute respiratory distress with resulting cyanosis and shock. Radiological evidence of mediastinal widening or pleural effusion is common.

Gastrointestinal Anthrax: An acute illness, or post-mortem examination revealing severe abdominal pain and tenderness, nausea, vomiting, hematemesis, bloody diarrhea, anorexia, fever, abdominal swelling and septicemia.

Oropharyngeal Anthrax: An acute illness, or post-mortem examination revealing a painless mucosal lesion in the oral cavity or oropharynx, with cervical adenopathy, edema, pharyngitis, fever, and possibly septicemia.

Meningeal Anthrax: An acute illness, or post-mortem examination revealing fever, convulsions, coma, or meningeal signs. Signs of another form will likely be evident as this syndrome is usually secondary to the above syndromes.

Case classification Suspected An illness suggestive of one of the known anthrax clinical forms. No definitive, presumptive, or suggestive laboratory evidence of B. anthracis, or epidemiologic evidence relating it to anthrax.

Probable A clinically compatible illness that does not meet the confirmed case definition, but with one of the following: • Epidemiological link to a documented anthrax environmental exposure;

6

• Evidence of B. anthracis DNA (for example, by LRN-validated polymerase chain reaction) in clinical specimens collected from a normally sterile site (such as blood or CSF) or lesion of other affected tissue (skin, pulmonary, reticuloendothelial, or gastrointestinal); • Positive result on testing of clinical serum specimens using the Quick ELISA Anthrax-PA kit; • Detection of Lethal Factor (LF) in clinical serum specimens by LF mass spectrometry • Positive result on testing of culture from clinical specimens with the RedLine Alert test.

Confirmed A clinically compatible illness with one of the following: • Culture and identification of B. anthracis from clinical specimens by the Laboratory Response Network (LRN); • Demonstration of B. anthracis antigens in tissues by immunohistochemical staining using both B. anthracis cell wall and capsule monoclonal antibodies; • Evidence of a four-fold rise in antibodies to protective antigen between acute and convalescent sera or a fourfold change in antibodies to protective antigen in paired convalescent sera using Centers for Disease Control and Prevention (CDC) quantitative anti- PA IgG ELISA testing; • Documented anthrax environmental exposure AND evidence of B. anthracis DNA (for example, by LRN-validated polymerase chain reaction) in clinical specimens collected from a normally sterile site (such as blood or CSF) or lesion of other affected tissue (skin, pulmonary, reticuloendothelial, or gastrointestinal).

7

Arboviral neuroinvasive and non­ neuroinvasive diseases 2011 Case Definition CSTE Position Statement Numbers: 10-ID-18, 1